Cambridge Investment Research Advisors
IOVA icon

Cambridge Investment Research Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Cambridge Investment Research Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$697K Sell
167,570
-1,299
-0.8% -$4.93K ﹤0.01% 2642
2026
Q1 		$593K Buy
168,869
+130,976
+346% +$419K ﹤0.01% 2647
2025
Q4 		$103K Sell
37,893
-17,364
-31% -$40.2K ﹤0.01% 3698
2025
Q3 		$120K Buy
55,257
+8,308
+18% +$19.6K ﹤0.01% 3577
2025
Q2 		$81K Buy
46,949
+1,072
+2% +$2.67K ﹤0.01% 3492
2025
Q1 		$153K Buy
45,877
+5,237
+13% +$27K ﹤0.01% 3272
2024
Q4 		$301K Sell
40,640
-1,229
-3% -$11.4K ﹤0.01% 2828
2024
Q3 		$393K Buy
41,869
+5,535
+15% +$52.4K ﹤0.01% 2610
2024
Q2 		$291K Buy
36,334
+9,074
+33% +$97.2K ﹤0.01% 2726
2024
Q1 		$404K Buy
+27,260
New +$317K ﹤0.01% 2460

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Cambridge Investment Research Advisors's IOVA Position: Q2 2026 in Review

Cambridge Investment Research Advisors reduced its Iovance Biotherapeutics (IOVA) stake by 0.77% in Q2 2026, selling an estimated $4.93K and leaving 167,570 shares worth $697K. The position accounts for ﹤0.01% of the portfolio, ranked #2642.

Cambridge Investment Research Advisors first reported a position in IOVA in Q1 2024 and has held it in 10 quarters since. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Cambridge Investment Research Advisors held 167,570 shares of Iovance Biotherapeutics worth $697K as of Q2 2026.
  • Cambridge Investment Research Advisors sold 1,299 Iovance Biotherapeutics shares in Q2 2026, an estimated $4.93K.
  • Iovance Biotherapeutics made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #2642 holding.
  • Cambridge Investment Research Advisors first reported a position in Iovance Biotherapeutics in Q1 2024 and has held it in 10 quarters since.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.